Analyst Price Targets — CCAP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 10:54 am | Finian O'Shea | Wells Fargo | $12.00 | $11.99 | TheFly | Crescent Capital BDC price target lowered to $12 from $13 at Wells Fargo |
| May 15, 2026 12:45 am | — | Oppenheimer | $16.00 | $11.99 | TheFly | Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer |
| February 26, 2026 9:05 pm | Robert Dodd | Raymond James | $14.00 | $13.22 | StreetInsider | Crescent BDC (CCAP) PT Lowered to $14 at Raymond James |
| May 16, 2025 10:14 am | Finian O'Shea | Wells Fargo | $15.00 | $15.42 | TheFly | Crescent Capital BDC price target lowered to $15 from $16 at Wells Fargo |
| May 13, 2024 6:45 am | Finian O'Shea | Wells Fargo | $18.00 | $18.19 | TheFly | Crescent Capital BDC price target raised to $18 from $16.50 at Wells Fargo |
| May 10, 2024 9:59 am | Robert Dodd | Raymond James | $19.00 | $18.19 | TheFly | Crescent Capital BDC price target raised to $19 from $18 at Raymond James |
| April 25, 2022 8:42 am | — | Wells Fargo | $18.50 | $17.80 | Benzinga | Wells Fargo Maintains Overweight on Crescent Capital BDC, Lowers Price Target to $18.5 |
Latest News for CCAP
Crescent Capital BDC, Inc. faces ongoing headwinds, with a 19% dividend cut following rising non-accruals and declining investment income. Despite a steep 39% discount to NAV and a 12%+ yield, I remain cautious given persistent inflation and the potential for further downside. CCAP's Q1 saw net investment income drop to $0.38/share and non-accruals spike to 5.7% at cost, pressuring NAV and dividend sustainability.
Crescent Capital BDC, Inc. trades at a 39% NAV discount after a 19% dividend cut was announced due to falling NII. CCAP's non-accrual ratio doubled year-over-year to 3.6%, based on fair value, pressuring net investment income and dividend coverage. The portfolio is 92% first liens, and the forward dividend yield is 12%, with Q1'26 coverage at 1.0x.
Crescent Capital BDC, Inc. continues to underperform the index. Part of it is justified; part of it isn't. As of today, CCAP trades 40% below NAV and offers a yield of almost 13% that is underpinned by strong earnings coverage.
ACRE, CWST and CCAP have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2026.
CCAP, DAVA and RH have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CCAP.
U.S. House Trading
No House trades found for CCAP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.